- Samsung Biologics reported an operating profit of 338.58 billion won for the third quarter, which is 6.3% higher than last year, surpassing the estimate of 318.45 billion won.
- The net profit for the same period is recorded at 264.47 billion won, marking a 10% increase year over year, outperforming the estimated 236.02 billion won.
- Sales reached 1.19 trillion won, showing a 15% growth from the previous year and exceeding the market estimate of 1.1 trillion won.
- Investment analysts’ opinions are predominantly positive towards Samsung Biologics with 30 buy recommendations, 1 hold, and 1 sell.
- The performance comparisons are based on the company’s original disclosures regarding previous results.
“`
Samsung Biologics on Smartkarma
In recent analyst coverage on Smartkarma, Sanghyun Park discusses trading plays related to Samsung Biologics amidst the forced holding company conversion issue of Samsung C&T. The rise in Samsung Biologics’ share value is driving Samsung C&T’s holding company ratio to near 50%, potentially leading to a forced conversion. Park highlights potential actions by Samsung to avoid this situation, such as selling Biologics shares to lower the ratio. The post underscores the risks beyond a market cap of ₩80T and the strategies Samsung may employ to manage its assets and holding ratio.
On a positive note, analyst Tina Banerjee reports that Samsung Biologics is experiencing strong financial performance, with a 34% year-over-year revenue growth in 2Q24. The company has already secured substantial orders and is on track to surpass a KRW4 trillion annual revenue milestone. Additionally, Banerjee highlights significant achievements like securing a $1.1 billion CMO contract and gaining FDA approval for new biosimilars. These developments signal momentum for Samsung Biologics in the pharmaceutical and biotechnology sector, contributing to its growth and market presence.
A look at Samsung Biologics Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 1 | |
| Growth | 5 | |
| Resilience | 4 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Samsung Biologics shows a promising long-term outlook. With high scores in Growth and Momentum, the company is positioned to capitalize on future opportunities and maintain strong upward momentum in the market. Additionally, Samsung Biologics demonstrates resilience, indicating its ability to withstand challenges and navigate uncertainties. However, the lower scores in Value and Dividend suggest that investors may need to consider other factors when evaluating the company’s overall potential.
Samsung Biologics Co.,Ltd. stands out as a manufacturer of bio-healthcare products with a focus on developing, refining, and distributing biopharmaceutical products. This strong emphasis on innovation and distribution in the biopharmaceutical sector aligns well with its high scores in Growth and Momentum, indicating a bright future ahead for the company in the biotech industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
